Lawton Alison Frances
SEC-identified person · CIK 1542650 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Magenta Therapeutics, Inc. MGTA | Director | filed 2020–2026 |
| Proqr Therapeutics N.V. PRQR | Director | filed 2026–2026 |
| X4 Pharmaceuticals, Inc XFOR | Director | filed 2020–2024 |
| Spyre Therapeutics, Inc. SYRE | Director | filed 2020–2023 |
| Kaleido Biosciences, Inc. KLDO | Director · See Remarks | filed 2019–2020 |
| Verastem, Inc. VSTM | Director | filed 2012–2019 |
| Colucid Pharmaceuticals, Inc. CLCD | Director | filed 2016–2017 |
| Cubist Pharmaceuticals INC cbst | Director | filed 2012–2015 |
| Tempest Therapeutics, Inc. TPST | Chief Operating Officer | filed 2013–2013 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.